Kitamura H, Moriyama T, Izumi M, Yokoyama K, Yamauchi A, Ueda N, Kamada T, Imai E
First Department of Medicine, Osaka University School of Medicine, Japan.
Kidney Int Suppl. 1996 Jun;55:S101-3.
Angiotensin I-converting enzyme (ACE) plays a pivotal role in cardiovascular homeostasis and by activating angiotensin I into angiotensin II and inactivating bradykinin. These two peptides play antagonistic roles on the cardiovascular system by regulating vascular tone and vascular smooth muscle cell proliferation. Identification of the ACE gene as a genetic marker for various forms of cardiovascular disease is a recent result of the progress made in molecular biology and genetics. The insertion/deletion (ID) polymorphism of the ACE gene defined by the presence or absence of the 287 base pair Alu sequence situated in intron 16 has been investigated as a possible genetic marker for a variety of cardiovascular disease including myocardial infarction, essential hypertension, cardiomyopathy, and diabetic vascular complications. This paper reviews prior reports and briefly describes our recent study on the association of the ACE I/D polymorphism and antiproteinuric effect of ACE inhibitors in patients with proteinuria.
血管紧张素I转换酶(ACE)在心血管稳态中起着关键作用,它能将血管紧张素I激活为血管紧张素II,并使缓激肽失活。这两种肽通过调节血管张力和血管平滑肌细胞增殖,在心血管系统中发挥拮抗作用。将ACE基因鉴定为各种形式心血管疾病的遗传标记,是分子生物学和遗传学领域取得进展的最新成果。由位于第16内含子的287个碱基对Alu序列的存在与否所定义的ACE基因插入/缺失(ID)多态性,已被作为包括心肌梗死、原发性高血压、心肌病和糖尿病血管并发症在内的多种心血管疾病的可能遗传标记进行研究。本文回顾了先前的报告,并简要描述了我们最近关于ACE I/D多态性与ACE抑制剂对蛋白尿患者抗蛋白尿作用之间关联的研究。